Mammograhically detected breast cancers and the risk of axillary lymph node involvement: Is it just the tumor size?

被引:12
作者
Heimann, R [1 ]
Munsell, M [1 ]
McBride, R [1 ]
机构
[1] Univ Chicago, Pritzker Sch Med, Dept Radiat & Cellular Oncol, Div Biol Sci, Chicago, IL 60637 USA
关键词
breast cancer; mammography; axillary lymph nodes;
D O I
10.1097/00130404-200205000-00012
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
PURPOSE In early breast cancer the knowledge of the risk of axillary node involvement is important in determining local as well as systemic therapy. Because of the increased acceptance of mammography, there has been an increase in the diagnosis of small, mammographically detected tumors. The objective of this study is to determine whether mammographically detected breast cancers have a lower risk of axillary node involvement compared to those detected clinically. PATIENTS AND METHODS From our patient database of stage I and II breast cancer we identified 980 patients with tumors less than or equal to 2 cm whom had axillary node dissection. Four hundred thirty-five (44%) patients presented with abnormal mammograms without clinically palpable tumors; 545 (56%) patients had clinically detected tumors. The median size of the mammographically detected tumors is 1.0 cm, and the median size of the clinically detected tumors is 1.5 cm. The median age of the patients with mammographically detected tumors is 61 (range: 29-87) compared to 53 (range: 27-88) in those with palpable tumors. RESULTS Fourteen percent of the patients with mammographically detected tumors had positive axillary nodes compared to 26% of those with clinically detected tumors. Eight percent of patients with mammographically detected tumors had a single positive, while the clinically detected tumors 11% had a single positive node. Thirteen percent of patients with less than or equal to 1 cm tumors and 25% with tumors 1.1 cm to 2 cm had positive axillary nodes. Because the smaller size of the mammographically detected tumors could explain the lower proportion of positive axillary nodes, we analyzed separately the less than or equal to 1 cm tumors. In the group of less than or equal to 1 cm tumors, 9% had positive axillary nodes if they were mammographically detected compared to 19% if clinically detected. Four percent had a single positive node while 5% had multiple positive nodes. If the tumors were palpable and less than or equal to 1 cm 9% had a single positive node and 10% had multiple positive nodes, Mammographically detected tumors less than or equal to 1 cm had similar grade to clinically detected tumors. In multivariate analysis, method of detection remains a significant variable impacting on the risk of axillary node involvement even in tumors less than or equal to 1 cm. DISCUSSION The risk of axillary node involvement is lower in mammographically detected tumors compared to clinically detected tumors independent of tumor size or grade. Mammography detects tumors early in their metastatic progression. The majority of the axillary node-positive patients who are mammographically detected have a single positive axillary node. Method of detection may need to be considered when assessing the risk of axillary node involvement and incorporated in the staging.
引用
收藏
页码:276 / 281
页数:6
相关论文
共 41 条
[1]   Lymphatic mapping and sentinel node biopsy in the patient with breast cancer [J].
Albertini, JJ ;
Lyman, GH ;
Cox, C ;
Yeatman, T ;
Balducci, L ;
Ku, NN ;
Shivers, S ;
Berman, C ;
Wells, K ;
Rapaport, D ;
Shons, A ;
Horton, J ;
Greenberg, H ;
Nicosia, S ;
Clark, R ;
Cantor, A ;
Reintgen, DS .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1996, 276 (22) :1818-1822
[2]  
ARNESSON LG, 1994, EUR J SURG, V160, P271
[3]   2000 update of recommendations for the use of tumor markers in breast and colorectal cancer: Clinical practice guidelines of the American Society of Clinical Oncology [J].
Bast, RC ;
Ravdin, P ;
Hayes, DF ;
Bates, S ;
Fritsche, H ;
Jessup, JM ;
Kemeny, N ;
Locker, GY ;
Mennel, RG ;
Somerfield, MR .
JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (06) :1865-1878
[4]  
Cady B, 1996, ARCH SURG-CHICAGO, V131, P301
[5]  
CARTER CL, 1989, CANCER-AM CANCER SOC, V63, P181, DOI 10.1002/1097-0142(19890101)63:1<181::AID-CNCR2820630129>3.0.CO
[6]  
2-H
[7]   Impact of consolidation radiotherapy in patients with advanced breast cancer treated with high-dose chemotherapy and autologous bone marrow rescue [J].
Carter, DL ;
Marks, LB ;
Bean, JM ;
Broadwater, G ;
Hussein, A ;
Vredenburgh, JJ ;
Peters, WP ;
Prosnitz, LR .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (03) :887-893
[8]   Recent trends in US breast cancer incidence, survival, and mortality rates [J].
Chu, KC ;
Tarone, RE ;
Kessler, LG ;
Ries, LAG ;
Hankey, BF ;
Miller, BA ;
Edwards, BK .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1996, 88 (21) :1571-1579
[9]   BREAST SCREENING, PROGNOSTIC FACTORS AND SURVIVAL - RESULTS FROM THE SWEDISH 2 COUNTY STUDY [J].
DUFFY, SW ;
TABAR, L ;
FAGERBERG, G ;
GAD, A ;
GRONTOFT, O ;
SOUTH, MC ;
DAY, NE .
BRITISH JOURNAL OF CANCER, 1991, 64 (06) :1133-1138
[10]  
Eifel P, 2001, JNCI-J NATL CANCER I, V93, P979